Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541303 · ClinicalTrials.gov registry record · Early Phase 1
Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery
A Early Phase 1 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 124
- Enrollment target
NCT04541303: Completed Early Phase 1 study, sponsored by University of Missouri-Columbia.
NCT04541303 is a Early Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 124 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (134% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04541303, a Early Phase 1 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
Bleeding after Mohs micrographic surgery for skin cancer is a low risk complication that can occur. This study aims to determine the effect of a drug, often used to reduce bleeding, called tranexamic acid when applied topically to the skin wound after surgery.
Primary Outcome
Number of patients who call to report postoperative bleeding
Interventions
- DRUG Tranexamic acid
- DRUG normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2021-12-30 |
| Phase | Early Phase 1 |
What the finished NCT04541303 record still lists
NCT04541303 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (134% higher).
The record links to 0 conditions, and to 2 interventions - of which Tranexamic acid is the first listed.
NCT04541303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04541303 about?
NCT04541303 is a clinical study titled "Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery". Bleeding after Mohs micrographic surgery for skin cancer is a low risk complication that can occur. This study aims to determine the effect of a drug, often used to reduce bleeding, called tranexamic acid when applied topically to the skin wound after surgery.
What is the current status of trial NCT04541303?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 124 participants. The study started on 2020-10-08. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04541303?
The interventions under investigation include: Tranexamic acid (DRUG), normal saline (DRUG).
Who is sponsoring clinical trial NCT04541303?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04541303's enrollment target sits among peer trials
124 145th of 2000 higher than 1,854 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI